Evidence map›Paper›PMID 41410143›Full record

ReviewEuropean journal of immunology2025

The Antigen Presenting Capabilities of Group 3 Innate Lymphoid Cells: Insights Into Immunogenic or Tolerogenic Outcomes for T Cells.

Alessia Calabrò, Sayuri Yamazaki, Guido Ferlazzo, Stefania Campana

Abstract readReview
In one paragraph

Review in European journal of immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Alessia CalabròDepartment of Human Pathology "G. Barresi", Laboratory of Immunology and Biotherapy, University of Messina, Messina, Italy.
Sayuri YamazakiDepartment of Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Guido FerlazzoExperimental Pathology and Immunology-IRCCS Ospedale Policlinico San Martino, Genoa, Italy.ORCID 0000-0002-3874-8554
Stefania CampanaDepartment of Clinical and Experimental Medicine, University of Messina, Messina, Italy.

Funding

European Union CUP: C43C23000880006European Union PNRR-MCNT2-2023-12378122Italian Association for Cancer Research AIRC IG 30453Italian Ministry of Health RF-2018-12367242Supporting Researcher Exchange to Promote International Joint Research in Nagoya City University 242001
6 · The paper itself

Abstract

Group 3 innate lymphoid cells (ILC3s) are tissue-resident lymphocytes distributed across both lymphoid and non-lymphoid tissues, capable of mounting rapid immune responses. They are defined by expression of the transcription factor RORγt and comprise distinct subsets, including lymphoid tissue inducer-like cells expressing major histocompatibility complex class II (MHCII). These MHCII⁺ ILC3s can directly present antigens to CD4⁺ T cells, a function regulated by the transcriptional activator CIITA through a pathway similar to thymic epithelial cells. ILC3s contribute to immune homeostasis by limiting effector T cell responses and promoting regulatory T cell differentiation. However, under the influence of distinct cytokine milieus, such as IL-1β and IFN-γ, ILC3s undergo a maturation process, upregulating costimulatory molecules and enhancing their antigen-presenting capacity to activate CD4⁺ T cells. This dual functionality is highly plastic and influenced by tissue-specific environmental cues, enabling ILC3s to adapt their immunoregulatory roles according to local context. Overall, ILC3s now emerge as critical modulators of T cell activities, balancing tolerance and activation, with significant implications for host defense, autoimmunity, inflammation, and cancer.

Indexed as

Antigen PresentationCD4-Positive T-LymphocytesImmune ToleranceImmunity, InnateLymphocytesAnimalsCell DifferentiationHistocompatibility Antigens Class IIHumansLymphocyte ActivationNuclear ProteinsNuclear Receptor Subfamily 1, Group F, Member 3Trans-ActivatorsHistocompatibility Antigens Class IIMHC class II transactivator proteinNuclear ProteinsNuclear Receptor Subfamily 1, Group F, Member 3Trans-Activatorsantigen presentationgroup 3 innate lymphoid cells (ILC3s)ILC3 plasticityMHCIIT cell response

Identifiers

PMID41410143
PMCPMC12712874

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.